CASE REPORT

A case of drug-induced parkinsonism and tardive akathisia with e1143g polymerase γ mutation-innocent bystander or a culprit?

Pretty Sara Idiculla, Syed Taimour Hussain, Junaid Habib Siddiqui

1University of Missouri Health Care, 1 Hospital Drive, Columbia, Missouri-65212, United States, 2United Medical and Dental College, Karachi, Pakistan

ABSTRACT

Background and Aim: Polymerase γ (POLG) is a protein that plays a pivotal role in the replication of the mitochondrial genome. POLG-related disorders constitute a sequence of overlapping phenotypes that can present from early infancy to late adulthood. Parkinsonism is the most common movement disorder associated with POLG mutation. We also summarize all reported cases of POLG-related Parkinsonism, along with a literature review.

Case Description: We present the case of an 80-year-old male presented with complaints of episodic confusion, tremors, and restlessness. He has been on risperidone for psychosis. A normal DaT scan ruled out Parkinson’s disease, and molecular analysis for POLG was positive (E1143G). He was diagnosed with drug-induced Parkinsonism and tardive akathisia with an incidental POLG mutation. We conducted a molecular analysis in our patient due to his Parkinsonism and recurrent episodes of encephalopathy. E1143G mutation found in our case was coincidental and reported a non-pathogenic or benign variant in literature.

Conclusions: A literature search revealed 55 cases of “POLG-related Parkinsonism” that met our criteria. These mutations can clinically affect multiple organ systems. Parkinsonism is the most common movement disorder reported in association with POLG mutations. We conducted a molecular analysis in our patient due to his Parkinsonism and recurrent episodes of encephalopathy. E1143G mutation found in our case was coincidental and reported a non-pathogenic or benign variant in literature.

Relevance for Patients: E1143G is a non-pathogenic variant and multiple studies have shown that its co-occurrence with other POLG mutations can aggravate disease occurrence and severity. Literature findings and the experience from our own case indicate that the pathogenicity of E1143G is debatable, and future studies involving this particular variant may help understand its pathological consequences.

1. Introduction

A group of proteins replicates the mitochondrial deoxyribonucleic acid (mtDNA), a major one being DNA polymerase γ (POLG). POLG-related disorders constitute a continuum of overlapping phenotypes that can present from early infancy to late adulthood. The most common movement disorder found in association with POLG mutation is Parkinsonism. These patients usually show clinical symptoms at a young age and are commonly associated with progressive external ophthalmoplegia (PEO). We present an 80-year-old male with drug-induced Parkinsonism and tardive akathisia with an incidental POLG mutation. We performed a literature search to summarize all reported cases of POLG-related Parkinsonism.

2. Case Report

An 80-year-old Caucasian male with a past medical history of diabetes mellitus, chronic kidney disease stage III, obstructive sleep apnea, psoriatic arthritis on methotrexate, and
depression on mirtazapine; presented with complaints of episodic confusion of 5 years duration, restlessness, and tremors of 2 years duration.

The episodic confusion was associated with apparent auditory/visual hallucination and delusions and typically occurred at night. The inciting event was a recognized infection during most episodes. He was started on risperidone to be used intermittently during these attacks to control the psychotic symptoms. According to his wife, he has taken risperidone only a few times after beginning the medication.

The restlessness comprised repeated crossing and uncrossing legs, sitting and standing, and moving his arms around. It began 3 years after initiating antipsychotic medications. Around the same time, he also developed tremors in his hands bilaterally (right >left). It has remained stable, is present predominantly at rest, and does not affect his day-to-day activities. He denied any loss of sense of smell, change in facial expression, voice change, drooling, constipation, and orthostatic symptoms. He also reported no similar complaints among his family members.

On examination, he had symmetric, akinetic, rigid Parkinsonism, and prominent akathisia. His total Movement Disorders Society Unified Parkinson’s Disease Rating Scale score was 46/104. Sensory examination showed impaired vibration sense in bilateral lower limbs. We advised him to avoid risperidone, as this could explain his Parkinsonism. When there was no noticeable improvement, we started him on a trial of Sinemet. A DaT scan was normal, ruling out Parkinson’s disease. We prompted genetic testing due to the occurrence of marked encephalopathy from minor infections and Parkinsonism from low and intermittent doses of risperidone. Molecular analysis was positive for a heterozygous POLG mutation- c.3428 A >G, p. Glu1143Gly (E1143G).

At 85 years of age, follow-up demonstrated a good response to Sinemet. The patient denied any new delirium episodes and mentions his tremors and akathisia is still present but improving. He was diagnosed with drug-induced Parkinsonism and tardive akathisia, with an incidental POLG mutation and peripheral neuropathy, most likely due to poor diabetic control.

Although E1143G mutation is a non-pathogenic POLG variant (https://www.ncbi.nlm.nih.gov/clinvar/variation/VCV000021312.5), it could be a contributing factor to our patient’s clinical presentation.

3. Literature Review

A literature search was done on PubMed using the keyword “POLG-related Parkinsonism.” We included all reported cases in the English language in our review and excluded those without the relevant documentation. A total of 55 patients met our criteria.

Delgado-Alvarado et al. summarized 37 cases of POLG-related Parkinsonism from the year 2004 to 2014 [1]. Since then, 18 more cases were reported [2-11]. The characteristics of 19 patients, including ours, are summarized in Table 1 (2014–2020).

- The age of onset of clinical symptoms ranged from 10 to 80 years, with an average onset between the 3rd and 4th decade.
- Among the 56 cases, 30 (53.6%) were males, 25 (44.6%) were females, and 1 patient had no gender specified.
- The age of onset of Parkinsonism ranged between 18 and 78 years- 4 patients (8.5%) had the onset before 20 years, 10 patients (21.3%) had between 21 and 40 years, 21 patients (44.7%) had between 41 and 60 years, and 12 patients (25.5%) had the onset after 60 years of age. PEO was a common manifestation in most cases, except 13 patients (23.2%). Myopathy was present among 28 patients (50%) and neuropathy among 30 patients (53.6%).
- Among the 25 patients who underwent DaT scan, 16 patients (64%) were positive and 43 patients (76.8%) showed good response to treatment with dopaminergic medications.

4. Discussion

The mitochondria are known as the cell’s powerhouse, generating adenosine triphosphate. Through the electron transport chain, this allows the proper functioning of cells, including the neurons. Multiple proteins that make up the system are derived from the mitochondrial genome, consisting of circular mtDNA.

POLG is a major DNA-binding protein involved in mDNA replication. POLG-related disorders can present with clinically overlapping symptoms in affected individuals. However, they are characterized into six clinical forms-

- Alpers-Huttenlocher syndrome- severe progressive encephalopathy, intractable epilepsy, and liver failure.
- Myocerebrohepatopathy spectrum- developmental delay, lactic acidosis, myopathy, and hepatic impairment.
- Myoclonic epilepsy myopathy sensory ataxia- a spectrum of epilepsy, myopathy, ataxia, and disorders previously described as a spinocerebellar ataxia with epilepsy.
- Axial neuropathy spectrum- sensory ataxia, neuropathy, dysarthria, ophthalmoplegia, and mitochondrial recessive ataxia syndrome.
- Autosomal recessive PEO- progressive extraocular muscle weakness causing ptosis and ophthalmoplegia without any systemic involvement.
- Autosomal dominant PEO- generalized myopathy, sensorineural hearing loss, axonal neuropathy, depression, Parkinsonism, hypogonadism, and cataracts.

Clinical signs and symptoms associated with POLG mutations include hypotonia, developmental delay, myoclonus, focal motor seizures, generalized seizures, status epilepticus, migraine, stroke-like episodes, Parkinsonism, chorea, sensory neuropathy, ganglionopathy, axonal sensorimotor neuropathy, cerebellar ataxia, depression, psychosis, dementia, sensorineural hearing loss, PEO/ptosis, catareks, retinopathy, liver failure, gastrointestinal dysmotility, proximal myopathy, exercise intolerance, diabetes mellitus, primary ovarian failure, ovarian dysgenesis, primary testicular failure, and cardiomyopathy [12].

Parkinsonism is the most common movement disorder associated with POLG mutations. The exact mechanism by which mitochondrial dysfunction leads to Parkinsonism is still not well understood. The existing hypothesis indicates that an alteration
### Table 1. Reported cases of POLG mutation Parkinsonism (2014-2020)

| Case | Age of onset (years) | Gender | Gene testing-Mutation | Onset of Park (years) | PEO | Myo | Neu | Other features | DaT scan | DA med |
|------|----------------------|--------|-----------------------|-----------------------|-----|-----|-----|----------------|----------|--------|
| 1    | Miguel et al. [2]    | 56     | Male                  | P648R P587L W585X     | 56  | -   | +   | • Ptosis       | +        |        |
| 2    | Miguel et al. [2]    | 46     | Female                | T251I P587L W585X     | 60  | +   | +   | • Ptosis       | +        |        |
| 3    | Miguel et al. [2]    | 39     | Male                  | P648R R807C           | 49  | +   | +   | • Ptosis       | +        |        |
| 4    | Martikainen et al. [3]| 50s    | Male                  | A467T                 | 72  | -   | -   | • Short-term memory problems | +        |        |
| 5    | Martikainen et al. [3]| 40s    | Male                  | T955C                 | -   | +   | +   | • Cerebellar ataxia | +        |        |
| 6    | Martikainen et al. [3]| 50s    | Female                | T251I P587L           | 67  | +   | +   | • RLS          | +        |        |
| 7    | Rempe et al. [4]     | 27     | Female                | G737R                 | 32  | -   | +   | • Mild ptosis  | +        |        |
| 8    | Mehta et al. [5]     | 18     | Male                  | E856K                 | 18  | -   | -   | • Dysarthria   | -        | +      |
| 9    | Mehta et al. [5]     | 19     | Female                | E856K                 | 19  | -   | -   | • Dysarthria   | -        | +      |
| 10   | Kuo et al. [6]       | 30     | Male                  | Y955C                 | 48  | +   | -   | • Ptosis       | +        |        |
| 11   | Schreglmann et al. [7]| 50     | Male                  | -                     | 50  | +   | -   | • SNP          | -        | +      |
| 12   | Schreglmann et al. [7]| 63     | Male                  | -                     | 68  | +   | -   | • Color blindness for blue | -        | +      |
| 13   | Schreglmann et al. [7]| 61     | Female                | -                     | 68  | -   | -   | • Ptosis       | -        | +      |
| 14   | Meira et al. [8]     | 72     | Male                  | T252I P587L R807C     | 72  | +   | -   | • Ataxia       | -        | -      |
| 15   | Hsieh et al. [9]     | 39     | Male                  | R964C                 | 39  | -   | -   | • RBD          | -        | +      |
| 16   | Hsieh et al. [9]     | 70     | Male                  | R964C                 | 70  | -   | -   | • Additional GBA L444P mutation | -        | +      |

(Contd...)
in the mtDNA can result in impaired protein synthesis resulting in mitochondrial dysfunction in the dopaminergic neurons [13]. Parkinsonism has been associated with both autosomal dominant and recessive POLG mutations and has an early age of onset, typically around the 3rd–4th decade [14]. Although patients with POLG-related Parkinsonism have associated PEO, studies have reported its occurrence without PEO [9]. Tzoulis et al. described 11 patients with POLG-related encephalopathy. The patients had no signs of Parkinsonism; however, DaTIL scans indicated severe nigrostriatal neuronal loss [15]. Degeneration of the nigrostriatal dopaminergic pigmented neurons is evident on DaTIL scans, and most cases respond to treatment with dopaminergic medications.

In 2004, Luoma et al. studied seven families, and for the 1st time, described a significant link between Parkinsonism and POLG mutations [16]. The extent to which POLG variants play a role in the development of Parkinson’s disease is still not established. Studies of patients with idiopathic Parkinson’s disease have shown an increase in mtDNA deletions and impairment of oxidative phosphorylation in nigrostriatal neurons [17]. Luoma et al. also conducted a post-mortem examination on two patients with POLG mutation. This revealed loss of pigmented dopaminergic neurons in the substantia nigra, though Lewy bodies were not seen [16]. Betts-Henderson et al. performed an autopsy on a patient with multiple heterozygous POLG mutations. Microscopic examination of the brain showed a severe neuronal loss in the substantia nigra and Lewy bodies’ presence in the remaining nigral neurons [18].

E1143G mutation is a non-pathogenic variant found at varying frequencies in different population subgroups (https://www.ncbi.nlm.nih.gov/snp/rs2307441?frequency%20tab). The mutation is rendered benign due to its occurrence outside the identified pathogenic cluster [19]. Sequence analysis of the E1143G variant by computer-based algorithms has yielded mixed results. While one indicated a benign mutation (http://www.snps3d.org/), another program predicted it to be damaging protein structure and function (http://genetics.bwh.harvard.edu/pph/). The commonly encountered pathogenic POLG variants include A467T, W748S, G848S, and T251I-P587L [20]. Studies have shown that the co-occurrence of E1143G with other POLG variants may aggravate the disease’s occurrence and clinical severity. Horvath et al. reported five patients with E1143G mutation, of which two individuals had compound mutations- A467T/E1143G and S433C/E1143G [21]. Chan et al. investigated the biochemical consequences of POLG proteins with E1143G polymorphism. They described that the occurrence of W748S in cis with E1143 mutation could modulate the former’s phenotypic effects [22].

Our patient was positive for a heterozygous POLG mutation- c.3428 A >G, p. Glu1143Gly (E1143G). The variant probably remained silent till the dopamine blocking effects of risperidone were in effect. It could also be contributing to his episodic encephalopathy and amplifying his drug-induced Parkinsonism.

5. Conclusion

The mutation identified in our patient, a benign heterozygous POLG variant (E1143G), was incidental. The pathogenicity of E1143G is debatable, and future studies involving this particular variant may help understand the pathological consequences when it occurs as single or compound mutations.

Conflicts of Interest

The authors declare that they have no competing interests.

References

[1] Delgado-Alvarado M, de la Riva P, Jiménez-Urbieta H, Gago B, Gabilondo A, Bornstein B, et al. Parkinsonism, Cognitive Deficit and Behavioural Disturbance Caused by a Novel Mutation in the Polymerase Gamma Gene. J Neurol Sci 2015;350:93-7.

[2] Miguel R, Gago MF, Martins J, Barros P, Vale J, Rosas MJ. POLG1-related Levodopa-Responsive Parkinsonism. Clin Neurol Neurosurg 2014;126:47-54.

[3] Martikainen MH, Ng YS, Gorman GS, Alston CL, Blakely EL, Schaefer AM, et al. Clinical, Genetic, and Radiological Features of Extrapyramidal Movement... DOI: http://dx.doi.org/10.18053/jctres.07.202103.001
Disorders in Mitochondrial Disease. JAMA Neurol 2016;73:668-74.

[4] Rempe T, Kuhlenbäumer G, Krüger S, Biskup S, Matschke J, Hagel C, et al. Early-onset Parkinsonism Due to Compound Heterozygous POLG Mutations. Parkinsonism Relat Disord 2016;29:135-7.

[5] Mehta SH, Dickson DW, Morgan JC, Singleton AB, Majounie E, Sethi KD. Juvenile onset Parkinsonism with “Pure Nigral” Degeneration and POLG1 Mutation. Parkinsonism Relat Disord 2016;30:83-5.

[6] Kuo PH, Lo RY, Tanji K, Kuo SH. Clinical Reasoning: A 58-Year-Old Man with Progressive Ptosis and Walking Difficulty. Neurology 2017;89:e1-5.

[7] Schreglmann SR, Riederer F, Galovic M, Ganos C, Kägi G, Waldvogel D, et al. Movement Disorders in Genetically Confirmed Mitochondrial Disease and the Putative Role of the Cerebellum. Mov Disord 2018;33:146-55.

[8] Meira B, Roque R, Pinto M, Caetano A. Late-onset Presentation of POLG1-Associated Mitochondrial Disease. BMJ Case Rep 2019;12:e228482.

[9] Hsieh PC, Wang CC, Tsai CL, Yeh YM, Lee YS, Wu YR. POLG R964C and GBA L444P Mutations in Familial Parkinson’s Disease: Case Report and Literature Review. Brain Behav 2017;9:e01281.

[10] Ma L, Mao W, Xu E, Cai Y, Wang C, Chhetri JK, et al. Novel POLG Mutation in a Patient with Early-onset Parkinsonism, Progressive External Ophthalmoplegia and Optic Atrophy. Int J Neurosci 2020;130:319-21.

[11] Chumrina M, Russ K, Azevedo C, Heuer A, Pihl M, Collin A, et al. Cellular Alterations Identified in Pluripotent Stem Cell-derived Midbrain Spheroids Generated from a Female Patient with Progressive External Ophthalmoplegia and Parkinsonism who Carries a Novel Variation (p. Q811R) in the POLG1 Gene. Acta Neuropathol Commun 2019;7:208.

[12] Cohen BH, Chinnery PF, Copeland WC. POLG-related Disorders. Seattle: University of Washington, Seattle.

[13] di Poggio MB, Nesti C, Bruno C, Meschini MC, Schenone A, Santorelli FM. Dopamine-Agonist Responsive Parkinsonism in a Patient with the SANDO Syndrome Caused by POLG Mutation. BMC Med Genet 2013;14:1-4.

[14] Davidzon G, Greene P, Mancuso M, Klos KJ, Ahlskog JE, Hirano M, et al. Early-onset Familial Parkinsonism Due to POLG Mutations. Ann Neurol 2006;59:859-62.

[15] Tzoulis C, Tran GT, Schwarzmüller T, Specht K, Haugarvoll K, Balafkan N, et al. Severe Nigrostriatal Degeneration without Clinical Parkinsonism in Patients with Polymerase Gamma Mutations. Brain 2013;136:2393-404.

[16] Luoma P, Melberg A, Rinne JO, Kaukonen JA, Nupponen NN, Chalmers RM, et al. Parkinsonism, Premature Menopause, and Mitochondrial DNA Polymerase γ Mutations: Clinical and Molecular Genetic Study. Lancet 2004;364:875-82.

[17] Bender A, Krishnan KJ, Morris CM, Taylor GA, Reeve AK, Perry RH, et al. High Levels of Mitochondrial DNA Deletions in Substantia Nigra Neurons in Aging and Parkinson Disease. Nat Genet 2006;38:515-7.

[18] Betts-Henderson J, Jaros E, Krishnan KJ, Perry RH, Reeve AK, Schaefer AM, et al. Alpha-synuclein Pathology and Parkinsonism Associated with POLG1 Mutations and Multiple Mitochondrial DNA Deletions. Neuropathol Appl Neurobiol 2009;35:120-4.

[19] Nurminen A, Farnum GA, Kaguni LS. Pathogenicity in POLG Syndromes: DNA Polymerase Gamma Pathogenicity Prediction Server and Database. BBA Clin 2017;7:147-56.

[20] Rahman S, Copeland WC. POLG-Related Disorders and their Neurological Manifestations. Nat Rev Neurol 2019;15:40-52.

[21] Horvath R, Hudson G, Ferrari G, Fütterer N, Ahola S, Lamantea E, et al. Phenotypic Spectrum Associated with Mutations of the Mitochondrial Polymerase γ Gene. Brain 2006;129:1674-84.

[22] Chan SS, Longley MJ, Copeland WC. Modulation of the W748S Mutation in DNA Polymerase γ by the E1143G Polymorphism in Mitochondrial Disorders. Hum Mol Genet 2006;15:3473-83.